key: cord-0735124-604f6o7c authors: Altawalah, Haya; AlHuraish, Fatma; Alkandari, Wafaa Ali; Ezzikouri, Sayeh title: Saliva specimens for detection of severe acute respiratory syndrome coronavirus 2 in Kuwait: A cross-sectional study date: 2020-10-01 journal: J Clin Virol DOI: 10.1016/j.jcv.2020.104652 sha: 3aad8652065413eb95e8b1adb0ef0cae47584a21 doc_id: 735124 cord_uid: 604f6o7c Coronavirus disease 2019 (COVID-19) is caused by severe acute respiratory syndrome coronavirus 2 (SARS-COV-2) and represents a global pandemic affecting more than 26 million people and has claimed >870,000 lives worldwide. Diagnostic tests for SARS-COV-2 infection commonly use nasopharyngeal swabs (NPS). As an alternative specimen, we investigated the potential use of the real-time reverse transcriptase PCR (RT-PCR) detection of SARS-COV-2 in saliva samples in large suspected-COVID-19 patients in Kuwait. NPS and saliva samples pairs were prospectively collected from 891 COVID-19 suspected patients in Kuwait and analyzed using TaqPath™ COVID-19 multiplex RT-PCR. Of the 891 patients, 38.61 % (344/891) were positive for SARS-CoV-2, 4.83 % (43/891) were equivocal, and 56.56 % (504/891) were negative with NPS by RT-PCR. For saliva, 34.23 % (305/891) were positive for SARS-CoV-2, 3.14 (28/891) were equivocal, and 62.63 % (558/891) were negative. From 344 confirmed cases for SARS-CoV-2 with NPS samples, 287 (83.43 %) (95 % CI, 79.14–86.99) were positive with saliva specimens. Moreover, the diagnostic sensitivity and specificity of RT-PCR for the diagnosis of COVID-19 in saliva were 83.43 % (95 % CI: 79.07–87.20) and 96.71 % (95 % CI: 94.85–98.04 %), respectively. An analysis of the agreement between the NPS and saliva specimens demonstrated 91.25 % observed agreement (κ coefficient = 0.814, 95 % CI, 0.775–0.854). This study demonstrates that saliva can be a noninvasive specimen for detection of SARS-CoV-2 by RT-PCR. In late December 2019, the coronavirus disease (COVID-19) occurred in Wuhan, China, and spread rapidly to become public health emergency of international concern, which is caused by severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection [1] [2] [3] [4] . The typical symptoms of COVID-19 are fever, dry cough, myalgias and/or fatigue, loss of smell and taste, sputum production, and shortness of breath 5, 6 . At present, there is no specific antiviral treatment recommended for COVID-19, and no vaccine is available 5 . Early diagnosis and isolation of infected individuals will play a vital role in stopping the further escalation of the pandemic 5 . SARS-CoV-2 has been detected in a variety of oral samples, including whole saliva, oral swabs, oropharyngeal swabs, and deep saliva/sputum [7] [8] [9] . Nasopharyngeal swabbing, followed by quantitative real-time reverse transcription polymerase chain reaction (RT-PCR) technique of the extracted RNA, is the gold standard for detection of SARS-CoV-2 infection 10, 11 . However, it has been reported that self-collected of saliva samples in comparison with nasopharyngeal swabs can greatly decrease the chance of exposing healthcare workers to SARS-CoV-2 8 . The potential use of saliva for the detection of SARS-CoV-2 infection appears clinically useful [12] [13] [14] , but further validation diagnostic accuracy studies comparing J o u r n a l P r e -p r o o f This was a cross-sectional study conducted among 891 suspected COVID-19 admitted consecutively to the Al-Sabah, Jaber, and Alrazi Hospitals, Kuwait between 19 and 21 July 2020. The study protocol was approved by the permanent Committee for Coordination of Medical To collect NPS, the swab was passed through the nostril until reaching the posterior nasopharynx and removed while rotating. After swabbing, each absorbent swab was placed immediately into a sterile tube with viral transport medium. Whole saliva (≈1.5 mL) was collected after deep cough from the suspected patients into a sterile container. Viscous saliva was added to 300 μL of viral transport media (VTM), mixed vigorously, and then 200 μL of sample was used for RNA isolation. NPS and saliva samples were collected at the same time. Samples positive for one or two targets were considered equivocal. For categorical variables, the Chi-square test was used. Differences in continuous variables were compared using the Mann-Whitney U test. Additionally, sensitivity, specificity, positive and negative predictive values and their 95% confidence intervals (CI) were calculated to assess diagnostic performance. Agreement between the NPS and saliva specimens for the virus detection ability was assessed using Cohen's Kappa (κ coefficient). Bland-Altman analysis was used to compare the cycle threshold (Ct) values between NPS and saliva. All P-values were two-sided and P<0.05 was considered significant. Statistical analyses were performed using GraphPad PRISM version 6.0e (GraphPad Software, San Diego, CA, USA) or MedCalc statistical software. J o u r n a l P r e -p r o o f Eight hundred ninety-one sample pairs of NPS and saliva samples were collected (Table 1) Throat swabs are the gold standard to diagnose COVID-19. However, NPS is relatively invasive, induce coughing and cause bleeding occasionally, which may increase risks of healthcare workers infection 17 . The use of saliva samples for diagnosis of COVID-19 has many advantages in clinical practice. First, collecting saliva is a non-invasive procedure and rather than nasal or throat swabs avoids patient discomfort. The second advantage of using saliva as specimen is related to possibility of collecting samples outside the hospitals 18 . In addition, saliva can be used to detect SARS-CoV-2 in both symptomatic patients and asymptomatic carriers 19 . There are several limitations to our study. Firstly, we have not evaluated the detection sensitivity regarding COVID-19 severity. Secondly, we don't have enough information regarding clinical data of COVID-19 patients. Moreover, saliva-based testing requires a careful preparation prior to RNA extraction and to get the right volume (minimum 1.5 mL). In this study, we found that the detection rate of SARS-CoV-2 by saliva RT-PCR was 83.43%. The result was in accordance with the previous studies and showed that the detection rate of SARS-CoV-2 ranges from 31% to 100 among COVID-19 patients 8, 13, 14, [20] [21] [22] . Moreover, the temporal profile of viral load in saliva reached the peak of viral load during the first week of symptom onset and then declined, but viral RNA could still be detected for 20 days or even longer 20 . Interestingly, Fakheran et al. reported that there is no statistically significant difference between nasopharyngeal and saliva samples regarding viral load 18 . In addition, previous data showed that angiotensin-converting enzyme II (ACE2) -SARS-CoV-2 host-cell receptoris expressed in the salivary glands and SARS-CoV-2 can be detected in saliva. These results confirm the possibility of the presence of SARS-CoV-2 in saliva 23 17 . Thus, several dental clinics in Japan are currently performing pre-clinical COVID-19 PCR tests using a saliva-based detection kit 24 . Our results showed that the saliva RT-PCR test demonstrated high sensitivity (83.43%) and specificity (96.71%) and comparable performance to the current standard of nasopharyngeal swab. This data seem in agreement with previous cross-sectional study (sensitivity and specificity of the saliva sample RT-PCR are 84.2% and 98.9%, respectively) 12 . Furthermore, in recent meta-analysis, the sensitivities for SARS-CoV-2 were 91% (95% CI, 80-99%) and 98% (95% CI, 89-100%) for saliva and for NPS samples, respectively 25 . Interestingly, Kim and al. revealed no significant difference in the sensitivity and specificity of saliva-and NPSbased tests for 11 different viral respiratory infections, including coronaviruses 26 . Recent study showed that saliva pools of either five or ten samples did not compromise the detection of SARS-CoV-2 27 . Moreover, the κ coefficient value showed a strong agreement of the diagnosis between the NPS and saliva specimen similar to previous data 12 . In conclusion, this study brought more evidence that saliva-based testing is a promising alternative sampling for SARS-CoV-2 detection by RT-PCR and could simplify and accelerate COVID-19 diagnosis. This study was supported by Ministry of Health, Kuwait. All authors declare that there are no conflicts of interests. J o u r n a l P r e -p r o o f Early Transmission Dynamics in Wuhan, China, of Novel Coronavirus-Infected Pneumonia China Novel Coronavirus I, Research T. A Novel Coronavirus from Patients with Pneumonia in China Weekly Epidemiological Update Coronaviridae Study Group of the International Committee on Taxonomy of V. The species Severe acute respiratory syndrome-related coronavirus: classifying 2019-nCoV and naming it SARS-CoV-2. Nat Microbiol Coronavirus disease 2019-Historical context, virology, pathogenesis, immunotherapy, and vaccine development Association of chemosensory dysfunction and COVID-19 in patients presenting with influenza-like symptoms Clinical features of patients infected with 2019 novel coronavirus in Wuhan Consistent Detection of 2019 Novel Coronavirus in Saliva Evaluating the use of posterior oropharyngeal saliva in a point-of-care assay for the detection of SARS-CoV-2 SARS-CoV-2 Viral Load in Upper Respiratory Specimens of Infected Patients Potential preanalytical and analytical vulnerabilities in the laboratory diagnosis of coronavirus disease 2019 (COVID-19) Saliva sample as a non-invasive specimen for the diagnosis of coronavirus disease 2019: a cross-sectional study Saliva is a reliable tool to detect SARS-CoV-2 Saliva as a Noninvasive Specimen for Detection of SARS-CoV-2 Saliva as a non-invasive sample for the detection of SARS-CoV-2: a systematic review COVID-19) Update: FDA Authorizes First Test for Patient At-Home Sample Collection Saliva: potential diagnostic value and transmission of 2019-nCoV Saliva as a diagnostic specimen for detection of SARS-CoV-2 in suspected patients: a scoping review Saliva as a Potential Diagnostic Specimen for COVID-19 Testing Temporal profiles of viral load in posterior oropharyngeal saliva samples and serum antibody responses during infection by SARS-CoV-2: an observational cohort study Molecular and serological investigation of 2019-nCoV infected patients: implication of multiple shedding routes Saliva as a Diagnostic Specimen for SARS-CoV-2 by a PCR-Based Assay: A Diagnostic Validity Study Detection of 2019-nCoV in Saliva and Characterization of Oral Symptoms in COVID-19 Patients Salivabased PCR tests for SARS-CoV-2 detection Saliva as a Candidate for COVID-19 Diagnostic Testing: A Meta-Analysis Comparison between Saliva and Nasopharyngeal Swab Specimens for Detection of Respiratory Viruses by Multiplex Reverse Transcription-PCR Saliva sample pooling for the detection of SARS-CoV-2 We acknowledge the contributions of other clinical and technical staff of the Al-Sabah, Jaber, and Alrazi Hospitals. We thank Sathishkumar Ramasamy, and Walled Khaled O Thajeil from Yacoub Behbahani center, virology unit.